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Abstract. Although non-alcoholic steatohepatitis (NASH)
may progress to cirrhosis and hepatocellular carcinoma
(HCC), no effective therapeutic modalities have been fully
established yet. Recent studies have shown that the renin-
angiotensin-aldosterone-system plays an important role in
NASH. The aim of our current study was to elucidate the
effects of aldosterone (Ald) inhibition on the progression of
NASH. In the choline-deficient L-amino acid-defined diet-
induced rat NASH model, the effects of a clinically used
selective Ald blocker (SAB) were elucidated in conjunction
with the activated hepatic stellate cells (HSC) and neovascular-
ization, which are both known to play important roles in liver
fibrosis development and hepatocarcinogenesis, respectively.
Liver fibrosis development and the glutathione-S-transferase
placental form-positive pre-neoplastic lesions were both
markedly attenuated by SAB along with the suppression of the
activated HSC and neovascularization. SAB inhibited the
hepatic expression of transforming growth factor-ß 1 and also
that of the vascular endothelial growth factor. Our in vitro
study showed that SAB also inhibited the Ald-induced HSC
proliferation and in vitro angiogenesis in a dose-dependent
manner. These results indicated that Ald plays a pivotal role in
the progression of NASH. Considering that SAB is already
widely used in clinical practice, this drug could represent a
potential new strategy against NASH in the future.
Introduction
Non-alchoholic fatty liver disease (NAFLD) ranges from
simple steatosis to cirrhosis. Fatty liver has been recognized
as a benign and non-progressive condition (1). However,
non-alcoholic steatohepatitis (NASH) is now widely known
as a potent liver disease which may progress to liver cirrhosis
and finally hepatocellular carcinoma (HCC) (2,3). Patients
with NAFLD have frequently presented clinical compli-
cations, such as obesity, type 2 diabetes mellitus, and insulin
resistance (4). While sustained weight loss should be very
effective in improving NAFLD, it is somewhat difficult for
many patients to change their lifestyle. Accordingly, efforts
are currently directed worldwide at overcoming NAFLD,
especially NASH. However, no widely accepted therapeutic
modalities have been established in clinical practice.
The renin-angiotensin-aldosterone system (RAAS) is a
key mediator in the regulation of arterial blood pressure and
body fluid homeostasis, and plays an important role in the
regulation of local hemodynamics in several organs. It has
been reported that angiotensin-II (AT-II), an octapeptide
produced via the enzymatic cleavage of angiotensin-I by the
angiotensin-I converting enzyme (ACE), plays an important
role in the progression of chronic liver diseases (5-7). Intra-
hepatic RAAS is up-regulated in experimental hepatic
fibrosis, and the serum AT-II levels are frequently elevated
in patients with cirrhosis (8,9). The AT-II antagonists
demonstrated antifibrotic activity in the animal models of
NASH and in clinical practice (10,11). Aldosterone (Ald),
which is positioned downstream of AT-II in RAAS, is a
mineralocorticoid hormone that acts classically on blood
pressure regulation and the electrolyte balance via the
mineralocorticoid receptors (MR). In addition to Ang II, Ald
is also implicated in liver damage and fibrosis (12). However,
the interaction between Ald and the progression of NASH is
still obscure.
In addition to liver fibrosis, AT-II plays a pivotal role in
HCC growth and hepatocarcinogenesis (7,13). It is now
widely recognized that angiogenesis is a crucial step in the
development of tumors, including HCC (14-16). Several
studies have revealed that neovascularization and angiogenic
factors, such as the vascular endothelial growth factor
(VEGF), are significantly up-regulated in human HCC
samples (16-18). Therapies targeting the tumor vessels have
proven successful for cancer treatment in experimental models
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(16,19,20). Several anti-angiogenic agents have already been
employed in clinical practice (21). Sorafenib, a multi-kinase
inhibitor that also targets VEGF receptors, has clearly
improved (i.e., prolonged) the overall survival of patients
with advanced HCC, and this drug is already approved in
many countries for the treatment of HCC (22). It is highly
probable that sorafenib will become the standard therapeutic
agent for the cure of the advanced stages of HCC in the near
future, but the long-term administration of this agent to
cirrhotic patients could lead to severe side-effects since drug
metabolism is usually hypoactive in these patients. As such,
almost all patients show adverse reactions with sorafenib,
such as hand-foot syndrome, and certain symptoms are very
severe. Furthermore, these recently developed agents are
very expensive (23). An alternative approach could be to find
a clinically available compound that also exhibits anti-angio-
genic activity, of which the safety of long-term administration
has been proven.
We have previously reported that AT-II suppression by
the ACE inhibitor suppressed HCC growth and hepato-
carcinogenesis via angiogenesis inhibition (5,7,16). Similar
to AT-II, it has been suggested that Ald plays an important
role in angiogenesis. Now, a selective Ald blocker (SAB) is
clinically used for the treatment of hypertension and heart
failure in many countries, including Japan. We found that
treatment with SAB exerted a marked inhibitory effect on the
HCC growth along with the suppression of VEGF-mediated
angiogenesis (24). However, the role of Ald and the effects
of SAB on hepatocarcinogenesis have not yet been elucidated.
The present study was conducted in order to examine the
effects of SAB on liver fibrosis and hepatocarcinogenesis in
a rat NASH model induced by rats feeding on a choline-
deficient, L-amino acid-defined diet (CDAA) (10,25). We also
attempted to investigate the possible mechanisms involved.
Materials and methods
Animals and reagents. A total of 30 male 6-week-old Fischer
344 rats were purchased from Japan SLC, Inc. (Hamamatsu,
Shizuoka, Japan). They were housed under controlled
temperature conditions and relative humidity, with 10-15 air
changes/h and light illumination for 12 h/day. SAB was
purchased from Pfizer Inc. (Tokyo, Japan). Ald and
conventional chemical agents were purchased from Nacalai
Tesque (Kyoto, Japan). Control solutions were prepared in
ethanol for Ald and in dimethyl sulfoxide (DMSO) for SAB.
The human umbilical vascular endothelial cells (HUVECs)
were obtained from the Japanese Cancer Research Resources
Bank (Tokyo, Japan) and Kurabo (Osaka, Japan). The cells
were grown in a supplier-recommended medium.
Animal treatment. The experimental period in all experiments
was 16 weeks. Group (G) 1 consisted of untreated rats that
served as the control group, and received a choline-sufficient
L-amino acid-defined (CSAA) diet. The rats in G2 and G3
received CDAA diet. In G3, the rats received 100 mg/kg/day
of SAB starting from week 12 by gavage. The dose of SAB
in the current study was almost comparable to that used in
clinical practice (26). The animals were allowed free access
to food and water throughout the acclimation and experimental
protocols. The rats were sacrificed on day 84 (week 12).
Several serum markers, such as alanine aminotransferase
(ALT), were assessed by routine laboratory methods. All
animal procedures were performed according to approved
protocols and in accordance with the recommendations for
the proper care and use of laboratory animals.
Histological and immunohistochemical staining and
quantification. In all the experimental groups, the first
section was routinely stained with hematoxylin and eosin for
histological examination. Another section was stained with
Sirius red for the detection of fibrosis development. Immuno-
histochemical staining for the ·-smooth muscle actin (·-SMA)
(Dako, Kyoto, Japan) and the enzyme-altered pre-neoplastic
lesions; namely, the placental form of glutathione-S-trans-
ferase (GST-P) (MBL Co. Ltd., Nagoya, Japan), were
performed as described previously (27). For the determination
of in vivo angiogenesis, we performed the immunohisto-
chemical analysis of the platelet/EC adhesion molecule
CD31, which is widely used as a marker of neovascularization,
in frozen sections of the liver as described previously (28).
The immunostained microvessel length was assessed under
200x magnification. In counting, the large vessels with a
thick muscular wall or with a lumen greater than 50 μm in
diameter were excluded. These immunopositive vessels were
evaluated with Adobe Photoshop and NIH image software as
described previously (29).
Expression of transforming growth factor (TGF)-ß and
VEGF in the liver. The TGF-ß and VEGF expression levels
in the liver were measured by an enzyme-linked immuno-
sorbent assay (ELISA) kit (Bender MedSystems and R&D
Systems, Tokyo, Japan) according to the manufacturer's
instructions. Liver lysates were prepared as described
previously (30), and the samples were equalized for protein
concentration prior to measuring the protein levels.
In vitro assays. The hepatic stellate cells (HSC) were purified
from F344 rats by the sequential digestion of the liver with
pronase and collagenase as previously described (31). The cell
purity, assessed by examining the autofluorescence properties
of the stored retinoids in HSC, was typically between 90 and
95%. HSC were cultured in Dulbecco's Modified Eagle's
Medium (Nakarai, Kyoto, Japan) supplemented with 10%
fetal bovine serum and 2 mM L-glutamine and then cultured
in a 95% air-5% CO2 humidified atmosphere at 37˚C. The
growth medium was changed every other day. HSC were
activated by culturing on plastic for 7 days (32). The effects
of Ald and SAB on the proliferation of HSC and HUVECs
were determined by tetrazolium, 3-(4, 5-dimethylthiazol-2,5-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay as
described previously (33). The cell proliferation was
quantified via the conversion of MTT by cells cultured in 48-
well plates. The cells were incubated with Ald and/or SAB at
various concentrations for 24 h, and MTT was added to each
well at a final concentration of 5 mg/ml. After 4-h incubation
at 37˚C with MTT, the untreated MTT and medium were
removed and 2 ml DMSO were added to solubilize the MTT
formazan. After gentle agitation for 10 min, the absorbance
of each well, which is directly proportional to the number of
NOGUCHI et al:  SELECTIVE ALDOSTERONE BLOCKER AMELIORATES THE PROGRESSION OF NASH408
407-413.qxd  15/7/2010  12:32 ÌÌ  ™ÂÏ›‰·408
living cells, was measured with a 540-nm filter. The effects
of Ald and SAB on the extracellular-signal regulated kinase
1/2 (ERK1/2) phosphorylation in HUVECs were evaluated
by the Cellular Activation of Signaling ELISA kit (Active
Motif, Tokyo, Japan), according to the manufacturer's
protocol. The in vitro angiogenesis was assessed as the
formation of capillary-like structures of HUVECs co-cultured
with human diploid fibroblasts as described previously (34).
The experimental procedure was carried out according to the
instructions provided with the angiogenesis kit (Kurabo). The
computer-assisted quantitation of tubule formation was
performed as in the in vivo assay.
Statistical analysis. For the assessment of the statistical
significance of inter-group differences in the quantitative data,
Bonferroni's multiple comparison test was performed after
one-way ANOVA. This was followed by Bartlett's test to
determine the homology of variance.
Results
General findings in the CSAA- and CDAA-treated rats. The
data for the effective numbers of rats, final body and relative
liver weights in all experimental groups are shown in Table I.
The SAB treatment did not cause any alteration in several
indices, such as the ALT level and Alb. Neither ascites nor
other organ abnormalities were observed at the end of the
experiment in any of the groups. In the CDAA model, the
final body and relative liver weights of the CDAA-treated
rats (G2, and 3) were less than those of the CSAA-treated
rats (G1), as stated in previous reports (35). The relative liver
weights in G2 and G3 were greater than those in G1.
Effects of SAB on the liver fibrosis development. We first
examined the effects of clinically comparable doses of SAB
on the development of liver fibrosis. As shown in Fig. 1,
SAB-treatment (G3) showed a significant inhibitory effect on
liver fibrosis development compared to the control group (G2)
(P<0.01). Semi-quantitative analysis revealed that the fibrosis
area in G3 was almost half that in G2. We then carried out an
immunohistochemical analysis of ·-SMA to examine the
effect of SAB on HSC activation during liver fibrosis develop-
ment. The activated HSC, which express ·-SMA, were
drastically reduced in the liver of the SAB-treated groups.
This was similar to the effect on fibrosis development (Fig. 2)
(P<0.01). We also examined TGF-ß, which is mainly produced
by the activated HSC. Compared to the rats that received a
CDAA diet, the ones that received SAB showed a decrease in
TGF-ß1 in the liver (P<0.01) (Fig. 4A). The inhibitory effect
of SAB on the TGF-ß1 expression was almost in parallel
with the inhibition of liver fibrosis.
Our in vitro study revealed that Ald at 10-8 M significantly
stimulated the activated HSC proliferation compared to the
untreated control, and that the Ald-induced activated HSC
proliferation was suppressed by SAB in a dose-dependent
manner (Fig. 5A).
Effects of SAB on the development of pre-neoplastic lesions.
We then examined the effect of SAB on the GST-P-pre-
neoplastic lesions in conjunction with neovascularization. As
shown in Fig. 3A, similar to the effect on liver fibrosis inhibi-
tion, SAB-treatment (G3) exerted a significant inhibitory
effect on the GST-P-positive pre-neoplastic lesion develop-
ment compared to the control group (P<0.01). In the CSAA-
treated rats, no GST-P-positive lesions were found. In order
to determine whether the inhibitory effect of SAB on the pre-
neoplastic lesion development was accompanied by the
suppression of neovascularization, we examined the
expression level of CD31. The treatment of SAB signifi-
cantly attenuated the CD31-positive vessels in the liver along
with the inhibition of GST-P-induced pre-neoplastic lesions
(Fig. 3B). In order to elucidate whether the suppressive effects
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Effective no. of rats 10 10 10
Final body weight (g)a 95±20 12±20c 210±18c
Relative liver weight 2.7±0.4 3.2±0.5b 3.1±0.4b
(g/100g body wt.)
ALT (IU/l) 54.4±18.7 275.5±18.4c 324.2±72.1c
Alb (g/dl) 4.0±0.3 4.2±0.5 4.0±0.2
T-bi (mg/dl) 0.10±0.03 0.12±0.02 0.12±0.02
–––––––––––––––––––––––––––––––––––––––––––––––––
aData represent mean ± SD. b,cStatisticaly significant compared to G1
(bP<0.05, c<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. Effects of the SAB on liver fibrosis development. (A)
Representative features of microphotographs in the liver sections from the
CDAA-treated rats. No fibrosis development could be observed in the
CSAA-treated control rats. The CDAA-treatment showed an extensive
fibrosis development along with fatty accumulation, and SAB-treatment
showed a significant inhibitory effect on liver fibrosis development at a
clinically comparable low dose (100 mg/kg). (B) Semi-quantitative analysis
revealed that the fibrosis area in G3 was almost half that in G2. The data
represent the mean ± SD (bars, n=10). **Indicates a statistically significant
difference between the indicated experimental groups (P<0.01). G1, CSAA-
treated control group; G2 and G3, CDAA-treated and CDAA with SAB-
treated group, respectively.
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of SAB on neovascularization were accompanied with the
inhibition of VEGF, we examined the VEGF expression in
the liver. As shown in Fig. 4B, the VEGF expression in the
liver was suppressed by the treatment with SAB (P<0.01).
We then performed a set of in vitro experiments. Ald at 10-8 M
significantly stimulated the in vitro EC proliferation compared
to the untreated control, and the Ald-induced EC prolifer-
ation was suppressed by SAB in a dose-dependent manner
(Fig. 5B). We also investigated the in vitro EC tubule
formation in the presence or absence of Ald and SAB. Similar
to the proliferation findings, Ald significantly stimulated
the EC tubule formation compared to the control. SAB
significantly inhibited the Ald-induced EC tubule formation
(Fig. 6A). We measured the total ERK1/2 (t-ERK) expression
and the phosphorylated ERK1/2 (p-ERK) expression in EC.
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Figure 2. Effects of SAB on the activated HSC in liver fibrosis development.
(A) Immunohistochemical analysis of the ·-SMA expression in the liver
from CSAA-diet rats, CDAA-diet rats and SAB-treated-CDAA-diet rats. (B)
The ·-SMA-positive cells were measured with an image analyzer system as
described in the Materials and methods. Treatment with SAB showed a
marked inhibitory effect on the ·-SMA expression in the liver as compared
to the CDAA-diet group. No significant ·-SMA expression was observed in
G1. The data represent the mean ± SD (bars, n=10). **Indicates a statistically
significant difference between the indicated experimental groups (P<0.01).
G1, CSAA-treated control group; G2 and G3, CDAA-treated and CDAA
with SAB-treated group, respectively.
Figure 3. Effects of SAB on the pre-neoplastic lesions and neovascularization.
(A) SAB-treatment exerted a significant inhibitory effect on the GST-P-
positive pre-neoplastic lesion development compared to the CDAA-treated
group. In the CSAA-treated rats, no GST-P-positive lesions were found. (B)
Treatment with SAB significantly attenuated the CD31-positive vessels in
the liver and this was almost in conjunction with the inhibition of GST-P-
pre-neoplastic lesions. The data represent the mean ± SD (bars, n=10).
**Indicates statistically significant difference between the indicated
experimental groups (P<0.01). G1, CSAA-treated control group; G2 and G3,
CDAA-treated and CDAA with SAB-treated group, respectively.
Figure 4. Effects of SAB on the hepatic TGF-ß and VEGF protein
expression. The TGF-ß (A) and VEGF (B) protein levels were measured by
ELISA as described in the Materials and methods. Treatment with SAB
showed a significant inhibitory effect on the TGF-ß and VEGF protein
expression in the liver compared to the CDAA-diet group. The data
represent the mean ± SD (bars, n=10). **Indicates a statistically significant
difference between the indicated experimental groups (P<0.01). G1, CSAA-
treated control group; G2 and G3, CDAA-treated and CDAA with SAB-
treated group, respectively.
Figure 5. Effects of Ald and SAB on the activated HSC and EC proliferation
in vitro. The cells were incubated in the presence of Ald (Ald) and SAB
for 24 h, and the proliferation was measured by MTT assay as described in
Materials and methods. (A) The Ald (10-8 M)-induced activated HSC
proliferation was suppressed by the treatment with SAB (from 10-7 to 10-5 M)
in a dose-dependent manner. (B) The Ald (10-8 M)-induced EC proliferation
was suppressed by the treatment with SAB (from 10-7 to 10-5 M) in a dose-
dependent manner. Each bar represents the mean ± SD (n=5). *,**Indicate
statistically significant differences between the indicated experimental
groups (P<0.05 and <0.01, respectively).
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As shown in Fig. 6B, Ald significantly increased p-ERK
whereas no marked change could be observed in t-ERK.
SAB significantly suppressed the Ald-induced p-ERK and
the ratio of p-ERK/t-ERK.
Discussion
Ald is secreted by the cells of the zona glomerulosa upon
stimulation with Ang-II, and it regulates blood volume
homeostasis. Besides this hormonal effect, Ald can be
synthesized in the extra-adrenal tissue, e.g., heart and blood
vessels (36-38). Ald is now recognized as a multifunctional
protein. Recent studies have shown that Ald participates in
endothelial dysfunction, vascular fibrosis, and in the
inflammation of the vasculature. Although its deleterious
pro-fibrogenic effects on the cardiovascular system are well
known, little information is available on the Ald effects on
liver fibrogenesis (38-40). In the current study, we revealed
that Ald plays an important role in liver fibrosis development,
and that SAB markedly attenuated fibrogenesis along with
the suppression of the activated HSC. The hepatic level of
TGF-ß, which is mainly produced in the activated HSC, was
also suppressed by treatment with SAB at a similar magnitude.
These results confirmed that the anti-fibrotic effect of SAB
was achieved by the suppression of HSC activation. Previous
reports have shown that anti-Ald agents, such as spiro-
nolactone and canrenone, could suppress experimental liver
fibrosis (40-42). These anti-Ald drugs are commonly used as
diuretics in the treatment of cirrhotic ascites, either alone or
in association with loop diuretics. However, their use is
associated with progestational and anti-androgenic side
effects due to their promiscuous binding to other steroid
receptors. These are most commonly manifested as gyneco-
mastia, an abnormal menstrual cycle, and impotence, limiting
their use by physicians in chronic liver disease. On the
contrary, SAB is a selective MR antagonist with minimal
binding to other steroid receptors such as progesterone and
androgen, and its selectivity is 100 times more than that of
spironolactone. Considering that long-term administration is
required for anti-fibrotic treatment, and taking into account
the previous reports on spironolactone, our study on SAB
proves that it is a more likely candidate for future clinical
application.
In addition to liver fibrosis development, we observed the
inhibitory effects of SAB on pre-neoplastic lesions along
with the suppression of neovascularization and VEGF in the
liver. Regarding tumor growth, recent studies have revealed
that angiogenesis begins at a very early stage when the neo-
plastic cells contain only a few hundreds cells (43,44). We
have previously reported that the hepatic neovascularization
increased stepwise during hepatocarcinogenesis (19,20,45).
As such, we found neovascularization mainly in the GST-P-
positive lesions compared to the adjacent areas. It has been
suggested that the anti-angiogenic agents exert a much more
potent inhibitory effect on the size rather than on the number
of pre-neoplastic lesions (5). We have previously reported
that SAB exerted a significant inhibitory effect on the VEGF-
mediated neovascularization in HCC (24). This could be the
reason why SAB exerted a marked inhibitory effect on the
size of the pre-neoplastic lesions, but not on the number of
lesions. The direct interaction between the SAB treatment
and angiogenesis during hepatocarcinogenesis is currently
being evaluated at our laboratory.
Although previous studies conducted to determine the
molecular processes associated with fibrosis and angiogenesis
were performed independently, recent studies have revealed
that both biological phenomena emerged synergistically
(46,47). We, as well as others, reported that neovascular-
ization significantly increased during liver fibrosis develop-
ment (48-51). In the current study, we showed that, as in EC,
Ald acted on the activated HSC. Accordingly, it is possible
that the augmentation of Ald-mediated neovascularization
could also play a certain role in the development of liver
fibrosis.
The CDAA diet induces histological changes similar to
those of the human NASH, and therefore this model is
widely used as a NASH model (10,25,51). We also used this
model to elucidate the effect of SAB on the progression of
SAB, as was done for ARB in a previous study (10). However,
a downside of the CDAA model is that it does not exhibit
several common features of NASH, such as insulin resistance
and diabetes mellitus. In order to examine the precise
pharmacological action of any drug, it is important to
examine its therapeutic effect under the condition of insulin
resistance. We previously investigated the effect of ARB on
CDAA-induced liver fibrosis development in Otsuka Long-
Evans Tokushima fatty (OLETF) rats, which commonly have
obesity, diabetes mellitus, and insulin resistance. The
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Figure 6. Effects of SAB on the EC tubular formation and on ERK1/2 in
EC. (A) Representative features and index of the in vitro EC tubular
formation with the Ald and SAB treatment. Cont, untreated control group;
Ald, Ald (10-8 M)-treated group; SAB, Ald (10-8 M)- and SAB (10-5 M)-
treated group. Treatment with Ald increased the EC tubule formation
compared to the untreated control group, and SAB inhibited the Ald-induced
tubule formation. (B) ERK 1/2 phosphorylation in EC with Ald and SAB
treatment. The phosphorylated ERK 1/2 significantly increased in the Ald-
treated EC, and the Ald-induced ERK 1/2 phosphorylation was suppressed
by treatment with SAB. Similar to the EC proliferation, SAB suppressed the
ERK 1/2 phosphorylation. Cont, untreated control group; Ald, Ald (10-8 M)-
treated group; SAB, Ald (10-8 M)- and SAB (10-5 M)-treated group. The
results are expressed as the ratio of the phosphorylated ERK 1/2 (pERK) to
the total ERK 1/2 in EC. The data represent the mean ± SD (bars, n=8).
**Indicates a statistically significant difference between the indicated
experimental groups (P<0.01).
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therapeutic effect of SAB in the CDAA-induced OLETF rats
remains to be elucidated.
In summary, we showed here that Ald plays an important
role in the progression of NASH. The treatment with SAB
significantly inhibited liver fibrogenesis and carcinogenesis,
at least partly, via the suppression of activated HSC and neo-
vascularization, respectively. As this agent is already widely
used in clinical practice with great safety, it could represent a
potential new therapeutic strategy against the progression of
NASH in the future.
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